Cumberland Pharmaceuticals Inc. CPIX
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -98.28% | 15.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -98.80% | 64.95% | |||
| Cost of Revenue | -- | 126.67% | |||
| Gross Profit | -98.57% | 56.60% | |||
| SG&A Expenses | -77.32% | 46.24% | |||
| Depreciation & Amortization | -99.31% | 0.36% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -79.43% | 46.72% | |||
| Operating Income | -113.86% | 30.23% | |||
| Income Before Tax | -103.10% | 27.68% | |||
| Income Tax Expenses | -83.19% | 307.02% | |||
| Earnings from Continuing Operations | -100.08% | 26.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -115.29% | 104.82% | |||
| Net Income | -133.02% | 27.26% | |||
| EBIT | -113.86% | 30.23% | |||
| EBITDA | -402.92% | 64.50% | |||
| EPS Basic | -132.94% | 27.22% | |||
| Normalized Basic EPS | -107.29% | 28.54% | |||
| EPS Diluted | -132.94% | 27.38% | |||
| Normalized Diluted EPS | -107.29% | 28.54% | |||
| Average Basic Shares Outstanding | 0.02% | -0.01% | |||
| Average Diluted Shares Outstanding | 0.02% | -0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||